Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Blood advances·2026

Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026

Same author

CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link?

Blood advances·2026

Same author

Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia.

Science signaling·2026

Same author

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.

Blood advances·2025

Same author

A CHIP off the old (MDS) block.

Haematologica·2025

Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025

Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025

Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025

Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025

Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025

Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

How can one optimize induction therapy in AML?

Selina M Luger¹

¹Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.

Best Practice & Research. Clinical Haematology

|November 21, 2017

Summary

This summary is machine-generated.

The standard induction therapy for acute myeloid leukemia (AML) has remained unchanged for decades. Recent advancements include two new FDA-approved agents, CPX-351 and gemtuzumab ozogamicin, offering improved patient outcomes.

Keywords:

AML Acute myeloid leukemia Ara-C Azacitidine CPX-351 Cladribine Clofarabine Cytarabine Daunorubicin Etoposide Fludarabine Gemtuzumab ozogamicin Idarubicin Induction Vadastuximab talirine

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Experiment Videos

Last Updated: Feb 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

The standard induction therapy for acute myeloid leukemia (AML), the 7+3 regimen (cytarabine and daunorubicin), has been the cornerstone of treatment since 1973.
Despite its long-standing use, research has explored various strategies to enhance patient response and outcomes.

Observation:

Dose intensification, adding agents to the 7+3 regimen, developing novel agents, and modifying treatments for older patients are key areas of investigation.
Two novel agents, CPX-351 and gemtuzumab ozogamicin, have recently received US Food and Drug Administration (FDA) approval.

Findings:

The review examines the evolution of induction therapy strategies for AML.
It analyzes the impact of these strategies, including the newly approved agents, on patient outcomes.

Implications:

The introduction of CPX-351 and gemtuzumab ozogamicin represents a significant advancement in AML induction therapy.
These novel agents hold promise for improving treatment efficacy and patient survival in AML.
Further research and clinical application of these agents are expected to refine AML treatment paradigms.